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1. INTRODUCTION {#jmv25499-sec-0050}
===============

Lower respiratory tract infection (LRTI) is one of the top five causes of death in children aged less than 5 years.[1](#jmv25499-bib-0001){ref-type="ref"} Various pathogens cause LRTIs. However, pathogen detection in the initial stage of disease has long been a serious challenge, limiting the guiding function of pathogen detection. In 2008, the xTAG RVP assay based on polymerase chain reaction (PCR), which allowed the simultaneous detection of 12 respiratory viruses, was approved by the Food and Drug Administration.[2](#jmv25499-bib-0002){ref-type="ref"} Since then, an increasing number of commercialized multiplex PCR kits have been developed, allowing the simultaneous detection of a large panel of viruses and atypical bacteria in clinical practice.[3](#jmv25499-bib-0003){ref-type="ref"} Several studies used this molecular diagnostic tool to show that viral infections accounted for a large proportion of LRTIs. In addition, mixed infections were identified frequently.[4](#jmv25499-bib-0004){ref-type="ref"}, [5](#jmv25499-bib-0005){ref-type="ref"}, [6](#jmv25499-bib-0006){ref-type="ref"}

Several studies discussed the clinical characteristics of coinfection compared with single virus infection, but most of them analyzed on a general basis or focused solely on respiratory syncytial virus (RSV).[5](#jmv25499-bib-0005){ref-type="ref"}, [6](#jmv25499-bib-0006){ref-type="ref"}, [7](#jmv25499-bib-0007){ref-type="ref"} As one of the most common pathogens of LRTI, human parainfluenza virus (HPIV) is found worldwide, especially in children aged less than 5 years.[8](#jmv25499-bib-0008){ref-type="ref"} HPIV can cause severe respiratory infection and accounts for 9 to 30% inpatient children admitted due to acute respiratory infection.[9](#jmv25499-bib-0009){ref-type="ref"} An increasing number of recent studies focused on HPIV, especially the epidemiology and presentation of four types of HPIV.[10](#jmv25499-bib-0010){ref-type="ref"} However, a few studies discussed coinfections with HPIV. Therefore, this study aimed to investigate the viral and atypical bacterial etiology of LRTI in children and compare the clinical characteristics of HPIV single infection with those of coinfection.

2. METHODS {#jmv25499-sec-0060}
==========

2.1. Clinical data {#jmv25499-sec-0070}
------------------

This study was performed on LRTIs in children requiring hospitalization. It was conducted prospectively at the Pediatric Respiratory Department of Yuying Children\'s Hospital affiliated to Wenzhou Medical University, Zhejiang, China, from December 2013 to June 2015.

The inclusion criteria for this study were as follows: (1) children aged between 1 to 71 months; (2) hospitalization during the study period; (3) within 7 days of the disease at admission; and (4) a diagnosis of LRTI. The exclusion criteria for this study were as follows: (1) failure of PCR or insufficient sample and (2) incomplete clinical data. Patients with positive bacterial culture were excluded while analyzing the impact of HPIV single infection and coinfection. HPIV‐positive patients were divided into three groups based on the test results: HPIV single infection, coinfection with other viruses, and coinfection with atypical bacteria. The diagnosis of LRTI for each patient was performed by at least two attending physicians based on Zhu Futang Practice of Pediatrics, 8th edition.[11](#jmv25499-bib-0011){ref-type="ref"} It was defined according to the clinical symptoms, including severe cough, fever, tachypnea, wheezing, and respiratory distress signs such as nasal flaring, retraction, cyanosis, and abnormal auscultatory findings (wheezing and crackles), or radiologic evidence indicative of an LRTI. Clinical syndromes of bronchitis, bronchiolitis, and pneumonia were included in the LRTI category. Bronchitis was diagnosed based on the clinical manifestations including severe cough with or without fever, symmetrical breath sounds without permanent rales on auscultation, and increased bronchovascular shadows in chest X‐ray examination. Bronchiolitis was recognized in patients aged \<24 months with lower respiratory symptoms of wheezing, tachypnea, and signs of respiratory distress such as nasal flaring, intercostal/subcostal retractions, and central cyanosis. The diagnosis of pneumonia was established based on clinical findings, including fever, tachypnea, and respiratory distress, with the presence of focal or diffuse crackles, decreased vesicular sounds, and radiographic findings such as patchy and macular shadows and/or atelectasis, and/or air bronchograms. The pertussis‐like cough was defined based on clinical signs including spasmodic cough, inspiratory whoop, and posttussive vomiting. Data included demographic information, subjective symptoms, physical examination findings, hospital course and management, radiographic findings, and laboratory results.

2.2. Collection of respiratory tract specimens and multiplex PCR detection {#jmv25499-sec-0080}
--------------------------------------------------------------------------

Nasopharyngeal secretions or sputum was obtained by sputum suction within 24 hours at entry. Pathogens were detected using advanced fragment analysis (AFA) based on multiplex PCR[12](#jmv25499-bib-0012){ref-type="ref"} provided by Ningbo Health Gene Technologies Ltd (Ningbo, China). The tested respiratory tract pathogens were influenza A virus (InfA, including pandemic influenza A virus‐2009 \[09H1\] and seasonal H3N2 virus \[H3\]), influenza B virus (InfB), RSV, adenoviruses (ADV), human rhinovirus (HRV), human bocavirus (HBoV), human metapneumovirus (HMPV), HPIV (including HPIV‐1, 2, 3, and 4), human coronavirus (HCoV, including OC43, 229E, NL63, and HKU1), Chlamydia (Ch, including *Chlamydia trachomatis* and *Chlamydia pneumoniae*), and *Mycoplasma pneumoniae* (MP). The details are provided in the Supporting Information Material.

2.3. Statistical analysis {#jmv25499-sec-0090}
-------------------------

The data were analyzed using SPSS (version 17.0; SPSS, Inc., IL). They were expressed as mean, standard deviation, median, quartile, frequency, and percentage. Continuous variables with a normal distribution were compared using analysis of variance, whereas other variables were compared using the Mann‐Whitney *U* test. The categorical data were evaluated using the *χ* ^2^ and Fisher\'s exact tests. A *P* value less than .05 was considered statistically significant (two‐tailed).

2.4. Ethics statement {#jmv25499-sec-0100}
---------------------

The study was submitted to the local ethics committee for approval. Oral information was given together with a paper explaining the content of the study. A consent form was signed by a parent or legal guardian before the inclusion of each patient in the study.

3. RESULTS {#jmv25499-sec-0110}
==========

3.1. Pathogen detection {#jmv25499-sec-0120}
-----------------------

The flow of the study is depicted in Figure [1](#jmv25499-fig-0001){ref-type="fig"}. A total of 1335 patients were enrolled in this study. The median age was 9 months (interquartile range, 4‐24 months) and ranged from 1 month to 71 months. The male‐to‐female ratio was 2:1. Among 1335 patients, 1181 (88.5%) were positive for at least 1 virus or atypical bacteria. The positive rate in children aged 1 to 11 months,12 to 35 months, and 36 to 71 months was 88.5% (684/773), 91.4% (352/385), and 81.9% (145/177), respectively. Children aged l to 11 months and 12 to 35 months had a higher positive rate compared with children aged 36 to 71 months (*χ* ^2^ = 5.586; *P*  *=* .018; *χ* ^2^ = 10.716; *P*  *=* .001). Viral infection was found in 1138 patients (85.2%). The pathogens identified most frequently were RSV, HRV, HPIV, ADV, and HMPV (Table [1](#jmv25499-tbl-0001){ref-type="table"}). The total coinfection rate was 24.8%. HCoV showed the highest coinfection rate of 65.0%, followed by InfB (63.9%), HBoV (59.3%), ADV (56.5%), and HRV (51.7%).

![Flow chart of the study. HPIV, human parainfluenza virus; LRTI, lower respiratory tract infection; PCR, polymerase chain reaction](JMV-91-1625-g001){#jmv25499-fig-0001}

###### 

Detection of respiratory pathogens using AFA

                                                                       Number of positive samples of potential pathogens                                                                                                
  -------------------------------------------------------------------- --------------------------------------------------- -------- -------- --------- --------- -------- -------- --------- -------- -------- -------- ----------------------------------------------------
  HPIV                                                                 **203**                                             3        5        39        17        4        9        13        8        10       3        15.2
  InfA                                                                                                                     **67**   6        7         9         2        0        0         2        2        1        5.0
  InfB                                                                                                                              **36**   2         7         1        0        2         0        1        0        2.7
  HRV                                                                                                                                        **414**   90        23       11       32        18       22       8        31.0
  RSV                                                                                                                                                  **440**   5        5        18        7        4        2        33.0
  HMPV                                                                                                                                                           **93**   2        4         2        1        0        7.0
  HCoV                                                                                                                                                                    **40**   4         2        2        0        3.0
  ADV                                                                                                                                                                              **115**   5        2        1        8.6
  HBoV                                                                                                                                                                                       **54**   0        0        4.0
  MP                                                                                                                                                                                                  **69**   0        5.2
  Ch                                                                                                                                                                                                           **25**   1.9
  1 Pathogen[^a^](#jmv25499-tbl1-note-0003){ref-type="fn"}             110                                                 43       13       200       299       56       14       50        22       30       13       63.7
  2 Pathogens[^b^](#jmv25499-tbl1-note-0004){ref-type="fn"}            77                                                  18       18       185       122       31       17       50        22       35       9        21.9
  3 Pathogens[^c^](#jmv25499-tbl1-note-0005){ref-type="fn"}            13                                                  4        4        25        15        5        9        13        8        3        3        2.5
  ≥4 Pathogens[^d^](#jmv25499-tbl1-note-0006){ref-type="fn"}           3                                                   2        1        4         4         1        0        2         2        1        0        0.4
  Coinfection rate (%)[^e^](#jmv25499-tbl1-note-0007){ref-type="fn"}   45.8                                                35.8     63.9     51.7      32.0      39.8     65.0     56.5      59.3     56.5     48.0     24.8[^f^](#jmv25499-tbl1-note-0008){ref-type="fn"}

*Note*: Boldface indicates total numbers of pathogens detected.

Abbreviations: ADV, adenovirus; AFA, advanced fragment analysis; Ch, chlamydia; HBoV, human bocavirus; HCoV, human coronavirus; HMPV, human metapneumovirus; HPIV, human parainfluenza virus; HRV, human rhinovirus; InfA, influenza A virus; InfB, influenza B virus; RSV, respiratory syncytial virus; MP, mycoplasma pneumoniae.

The number of single infection of a certain pathogen.

The number of certain pathogen coinfected with another pathogen.

The number of certain pathogen coinfected with other two pathogens.

The number of certain pathogen coinfected with more than two pathogens.

The coinfection rate of certain pathogen.

The total coninfection rate of all the detected pathogens.
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3.2. HPIV infection {#jmv25499-sec-0130}
-------------------

Among the 203 HPIV‐positive patients (55 female \[27.1%\] and 148 male \[72.9%\]), the median age at enrollment was 7 months (interquartile range, 3--13 months), ranging from 1 month to 71 months. A total of 32 (15.8%) among 203 patients had underlying diseases. Demographics of all the HPIV‐positive patients are shown in Table [2](#jmv25499-tbl-0002){ref-type="table"}. The positive rate of HPIV in children aged 1 to 11 months, 12 to 35 months, and 36 to 71 months was 17.5% (135/773), 15.1% (58/385), and 5.6% (10/177), respectively. Further comparison revealed that children aged 1 to 11 months and 12 to 35 months had higher positive rates compared with children aged 36 to 71 months (*χ* ^2^ = 15.544; *P*  *\<* .001; *χ* ^2 = ^10.106; *P*  *=* .001). No significant difference in the positive rate was observed between children aged 1 to 11 months and 12 to 35 months.

###### 

Demographics of all HPIV‐positive patients (n = 203)

  Characteristics                      n (%)
  ------------------------------------ ------------
  Male sex                             148(72.9)
  Age group                            
  Infant (1 to 11 m)                   135 (66.5)
  Toddler (12 to 35 m)                 58 (28.6)
  Preschool (36 to 71 m)               10 (4.9)
  Underlying diseases                  32(15.8)
  Atrial septal defect                 14(6.9)
  Ventricular septal defect            4 (2.0)
  Patent ductus arteriosus             4(2.0)
  Tracheobronchomalacia                4(2.0)
  Bronchial asthma                     2(1.0)
  Malnutrition                         2(1.0)
  Congenital laryngeal stridor         2(1.0)
  Bronchial pulmonary hypoplasia       1(0.5)
  Kawasaki disease                     1(0.5)
  Decrease in thyroid function         1(0.5)
  Lack of selective immunoglobulin A   1(0.5)

Abbreviation: HPIV, human parainfluenza virus.

John Wiley & Sons, Ltd.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

3.3. HPIV single infection and coinfection {#jmv25499-sec-0140}
------------------------------------------

The percentage of HPIV single infection, coinfection with bacteria, coinfection with other virus, coinfection with atypical bacteria, and multiple infection was 42.9% (87/203), 11.3% (23/203), 27.6% (56/203), 3.9% (8/203), and 14.3% (29/203), respectively. The highest rate of virus coinfection with HPIV was HRV (19.2%, 39/203), followed by RSV (8.4%, 17/203), ADV (6.4%, 13/203), HCoV (4.4%, 9/203), HBoV (3.9%, 8/203), InfB (2.5%, 5/203), HMPV (2.0%, 4/203), and InfA (1.5%, 3/203).

HPIV single infection was the most common in all age groups, following by coinfection with other viruses. In patients aged 1 to 11 months, 12 to 35months, 36 tp 71months, HPIV coinfection with other viruses accounted for 25.9% (35/135), 32.8%(19/58), and 20%(2/10), respectively. And 20% (2/10) of patients aged 36 to 71months were coinfected with atypical bacteria, which was far more than that in the other two groups (Figure [2](#jmv25499-fig-0002){ref-type="fig"}). A total of 52 bacteria‐positive patients were excluded. No statistically significant differences were observed in terms of gender, birth weight, preterm/full term, and underlying diseases (Table [3](#jmv25499-tbl-0003){ref-type="table"}).

![Distribution of infection status in HPIV‐positive patients according to age. HPIV, human parainfluenza virus](JMV-91-1625-g002){#jmv25499-fig-0002}

###### 

Demographic data of HPIV‐positive patients

                                                               HPIV single infection n = 87   Coinfection with other viruses n = 56   Coinfection with atypical bacteria, n = 8   *χ* ^2^/*F*   *P*
  ------------------------------------------------------------ ------------------------------ --------------------------------------- ------------------------------------------- ------------- -------
  Sex                                                                                                                                                                                           
  Male                                                         65(74.7)                       43(76.8)                                4(50.0)                                     2.653         0.265
  Female                                                       22(25.3)                       13(23.2)                                4(50.0)                                                   
  Age                                                                                                                                                                                           
  1‐11 m                                                       58(66.7)                       35(62.5)                                3(37.5)                                     5.037         0.283
  12‐35 m                                                      25(28.7)                       19(33.9)                                3(37.5)                                                   
  36‐71 m                                                      4(4.6)                         2(3.6)                                  2(25.0)                                                   
  Birth weight[^a^](#jmv25499-tbl3-note-0002){ref-type="fn"}   3.27 ± 0.65                    3.27 ± 0.53                             3.61 ± 0.66                                 1.218         0.299
  Preterm                                                      14(16.1)                       7(12.5)                                 0(0.0)                                      1.732         0.421
  Underlying diseases                                          14(16.1)                       10(17.9)                                0(0)                                        1.676         0.433

Abbreviations: HPIV, human parainfluenza virus.

The birth weight was measured in kilograms. The data were expressed as mean ± standard deviation. The others were numbers (%) of each group.
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The clinical characteristics of HPIV‐positive patients were compared(Table [4](#jmv25499-tbl-0004){ref-type="table"}). The most common diagnosis was pneumonia, followed by bronchiolitis and bronchitis. A few patients (5.4‐12.5%) in each group had a pertussis‐like cough. HPIV coinfection with other viruses was more associated with running nose and shortness of breath (*χ* ^2^ = 5.235; *P*  *=* 0.022; *χ* ^2^ = 7.87; *P*  *=* 0.005), and more patients needed oxygen support (*χ* ^2^ = 6.539; *P*  *=* 0.011) compared with HPIV single infection. Neutrophil percentage was higher in coinfection with viruses than in HPIV single infection (*χ* ^2^ = 5.744; *P*  *=* 0.017). Moreover, HPIV coinfection with atypical bacteria was more related to running nose (*χ* ^2^ = 6.511; *P*  *=* 0.011), moist rales (*χ* ^2^ = 5.167; *P*  *=* 0.023), and longer hospital duration (*χ* ^2^ = 5.904; *P*  *=* 0.015) compared with HPIV single infection, and also to longer hospital duration compared with coinfection with other viruses (*χ* ^2^ = 4.847; *P*  *=* 0.028).

###### 

Clinical characteristics of HPIV‐positive patients

                                                                               HPIV single infection n = 87   Coinfection with other viruses n = 56   Coinfection with atypical bacteria n = 8   *χ* ^2^   *P*
  ---------------------------------------------------------------------------- ------------------------------ --------------------------------------- ------------------------------------------ --------- -----------
  Diagnosis                                                                                                                                                                                                
  Bronchitis                                                                   9 (10.3)                       4 (7.1)                                 0 (0)                                      4.731     0.316
  Bronchiolitis                                                                31 (35.6)                      21 (37.5)                               1 (12.5)                                             
  Pneumonia                                                                    47 (54.0)                      31 (55.4)                               7 (87.5)                                             
  Symptoms                                                                                                                                                                                                 
  Fever                                                                        54 (62.1)                      34 (60.7)                               6 (75.0)                                   0.645     0.724
  Productive cough                                                             75 (86.2)                      53 (94.6)                               7 (87.5)                                   2.592     0.274
  Pertussis‐like cough                                                         7 (8.0)                        3 (5.4)                                 1 (12.5)                                   0.679     0.712
  Running nose                                                                 15 (17.2)                      19 (33.9)                               5 (62.5)                                   10.883    **0.004**
  Vomit or diarrhea                                                            23 (26.4)                      14 (25.0)                               1 (12.5)                                   0.757     0.685
  Shortness of breath                                                          6 (6.9)                        13 (23.2)                               0 (0)                                      9.463     **0.009**
  Cyanosis                                                                     3 (3.4)                        2 (3.6)                                 0 (0)                                      0.555     0.758
  Cough duration[^a^](#jmv25499-tbl4-note-0003){ref-type="fn"}                 11.0 (8.0,15.0)                13.0 (9.0,19.0)                         13.5 (13.0,17.8)                           3.962     0.138
  Wheezing duration[^a^](#jmv25499-tbl4-note-0003){ref-type="fn"}              7.0(0.0,10.0)                  6.0 (0.0,11.0)                          2.5 (0.0,4.0)                              2.727     0.256
  Fever duration[^a^](#jmv25499-tbl4-note-0003){ref-type="fn"}                 1.0(0.0,4.0)                   1.0 (0.0,4.0)                           5.0 (0.5,7.0)                              2.845     0.241
  Physical examination                                                                                                                                                                                     
  Three depression signs[^b^](#jmv25499-tbl4-note-0004){ref-type="fn"}         6 (6.9)                        8 (14.3)                                0(0)                                       3.075     0.215
  Moist rale                                                                   34 (39.1)                      30 (53.6)                               7(87.5)                                    8.994     **0.011**
  Wheezing rale                                                                58 (66.7)                      39 (69.6)                               6(75.0)                                    0.319     0.853
  Treatment                                                                                                                                                                                                
  Oxygen therapy                                                               6 (6.9)                        12 (21.4)                               0 (0)                                      7.996     **0.018**
  Duration of steroid therapy [^a^](#jmv25499-tbl4-note-0003){ref-type="fn"}   0.0 (0.0,4.0)                  0.0 (0.0,5.0)                           2.5 (0.0,4.0)                              1.659     0.436
  ICU duration[^a^](#jmv25499-tbl4-note-0003){ref-type="fn"}                   0.0 (0.0,0.0)                  0.0 (0.0,0.0)                           0.0 (0.0,0.0)                              0.736     0.692
  Hospital duration[^a^](#jmv25499-tbl4-note-0003){ref-type="fn"}              6.0 (4.0, 7.0)                 6.0 (4.0, 7.0)                          8.0 (6.0, 9.8)                             5.932     **0.049**
  Laboratory examination                                                                                                                                                                                   
  PCT\>0.5 ng/mL                                                               6 (9.7)                        3 (6.7)                                 0 (0)                                      1.667     0.434
  Peak of WBC count[^c^](#jmv25499-tbl4-note-0005){ref-type="fn"}              9.8 (7.4, 12.5)                10.5 (8.1, 13.7)                        9.6 (7.8, 16.6)                            2.253     0.324
  Neutrophil percentage                                                        33.9 (23.3, 48.6)              42.3 (32.1, 58.3)                       53.4 (32.0, 59.8)                          7.296     **0.026**
  Peak CRP[^d^](#jmv25499-tbl4-note-0006){ref-type="fn"} level                 4.0 (2.0, 6.3)                 6.0 (2.1, 10.8)                         6.5 (1.9, 30.5)                            2.701     0.259
  Leukocytosis[^e^](#jmv25499-tbl4-note-0007){ref-type="fn"}                   24 (27.6)                      21 (37.5)                               2 (25.0)                                   1.710     0.425
  CRP increase[^f^](#jmv25499-tbl4-note-0008){ref-type="fn"}                   18 (20.7)                      18 (32.1)                               3 (37.5)                                   2.934     0.231
  Leukopenia[^g^](#jmv25499-tbl4-note-0009){ref-type="fn"}                     9 (10.3)                       4 (7.1)                                 1 (12.5)                                   0.520     0.771

Abbreviations: CRP, C‐reactive protein; HPIV, human parainfluenza virus; PCT, procalcitonin; WBC, white blood cell.

Boldface indicates a *P* value of less than 0.05.

The duration was measured in days.

Three depression sighs were described as supraclavicular, suprasternal, or intercostal/subcostal retractions.

The unit for peak and bottom of WBC was 10^9^/L; the normal value was 4--12 × 10^9^/L.

The unit for CRP was mg/L; the normal value was 0--8 mg/L.

Leukocytosis was defined as WBC more than 12 × 10^9^/L.

CRP increase was defined as CRP more than 8 mg/L.

Leukopenia was defined as WBC less than 4 × 10^9^/L. The quantitative data were expressed as median(quartile). The count data were expressed as numbers (%) of each group.
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4. DISCUSSION {#jmv25499-sec-0150}
=============

A total of 1335 samples were tested for respiratory pathogens in the present study. The viruses positive rate was 85.2%. In studies performed in other countries, the number varied from 62.4% to 81.8%.[4](#jmv25499-bib-0004){ref-type="ref"}, [5](#jmv25499-bib-0005){ref-type="ref"}, [13](#jmv25499-bib-0013){ref-type="ref"}, [14](#jmv25499-bib-0014){ref-type="ref"}, [15](#jmv25499-bib-0015){ref-type="ref"} Viral infection has reached a consensus as the most common cause of respiratory tract illness. Several factors may lead to the diversity in the positive rate, such as the standard of enrollment, region, season, pathogen spectrum, and detection method.

The most frequently identified virus in this study was RSV (33.0%), followed by HRV (31.0%), HPIV (15.2%), ADV (8.6%), and HMPV (7.0%). This result was in line with the findings of other studies that investigated the etiology of acute respiratory infection (ARI) in hospitalized children.[5](#jmv25499-bib-0005){ref-type="ref"}, [16](#jmv25499-bib-0016){ref-type="ref"}, [17](#jmv25499-bib-0017){ref-type="ref"}, [18](#jmv25499-bib-0018){ref-type="ref"} HPIV was the third most frequent pathogen detected in the present study. MP‐ and Ch‐positive rate were low (5.2% and 1.9%, respectively) in the present study, indicating that they are not common pathogens in young children.

This study revealed a high coinfection detection rate of 24.8%. The previously reported rate was 18 to 65% in patients with ARI.[4](#jmv25499-bib-0004){ref-type="ref"}, [5](#jmv25499-bib-0005){ref-type="ref"}, [17](#jmv25499-bib-0017){ref-type="ref"}, [19](#jmv25499-bib-0019){ref-type="ref"} It appears that coinfections are related to the prolonged period of viral persistence in the mucosa of the respiratory tract.[20](#jmv25499-bib-0020){ref-type="ref"} The large difference in the coinfection rate is probably due to the age and severity of patients enrolled. Infants and toddlers have an extremely high rate of virus coinfection compared with older children and adults.[19](#jmv25499-bib-0019){ref-type="ref"}

Singleton et al[21](#jmv25499-bib-0021){ref-type="ref"} suggested that HPIV caused LRTI in hospitalized children, with a positive rate of 18%, which was in line with the value in the present study (15.2%). HPIV coinfection was high in the present study, accounting for 57.1% of all the HPIV infections. Coinfection with virus took the major part, of which HRV, RSV, and ADV were the most frequently detected agents. The fastest growing virus HRV was most commonly found in combination with HPIV, possibly due to the same age and seasonal distribution and the specific characteristics of the two viruses.[18](#jmv25499-bib-0018){ref-type="ref"}, [22](#jmv25499-bib-0022){ref-type="ref"} Children aged less than 3 years had a higher positive rate of HPIV compared with children older than 3 years, indicating that young children are vulnerable to respiratory infection.[15](#jmv25499-bib-0015){ref-type="ref"}, [16](#jmv25499-bib-0016){ref-type="ref"}, [17](#jmv25499-bib-0017){ref-type="ref"} Only eight patients were coinfected with HPIV and atypical bacteria in the present study. One hypothesis to explain the relative paucity of the codetections is that infections with these pathogens exhibit different age and seasonal distributions.

Several studies focused on the association between the severity of illness and coinfection, but no consensus has been reached. Some studies showed that viral coinfection did not increase severity,[17](#jmv25499-bib-0017){ref-type="ref"}, [23](#jmv25499-bib-0023){ref-type="ref"} some studies indicated that virus single infection increased the risk of severe situations,[24](#jmv25499-bib-0024){ref-type="ref"} while others suggested that patients with dual or mixed respiratory virus infections had an increased risk of being admitted to a general ward or intensive care unit (ICU) or having longer hospital stays.[7](#jmv25499-bib-0007){ref-type="ref"}, [25](#jmv25499-bib-0025){ref-type="ref"}, [26](#jmv25499-bib-0026){ref-type="ref"}, [27](#jmv25499-bib-0027){ref-type="ref"} These contradictory conclusions might indicate the necessity for further investigations, especially for specific viruses.

A few studies focused on the clinical features of HPIV coinfection with specific pathogens. This study analyzed HPIV single infection, coinfection with other viruses, and coinfection with atypical bacteria. In the present study, most HPIV‐positive patients had a mild clinical presentation, and only one patient had ICU experience. Coinfection with other viruses was associated with running nose and shortness of breath, and more patients needed oxygen inhalation compared with patients with HPIV single infection. This indicated the mild presentation of HPIV single infection compared with that of coinfection with other viruses. However, another study found no difference.[10](#jmv25499-bib-0010){ref-type="ref"} Many factors may be responsible for the absolute opposite conclusions, such as specific viruses involved in coinfection, order of infection, and number of viruses. Controlling these factors may be possible in an in vitro study, but this scenario is highly unlikely in patients. To date, a few experimental studies have been conducted on simultaneous respiratory infections, especially those caused by HPIV. It has long been known that simultaneous viral infections exhibit a phenomenon called viral interference, in which one virus blocks the growth of another virus.[28](#jmv25499-bib-0028){ref-type="ref"} The effect depends on the virus causing the primary infection,[29](#jmv25499-bib-0029){ref-type="ref"} number of viruses used to initiate an infection,[30](#jmv25499-bib-0030){ref-type="ref"} speed of virus replication, and delay between initial and secondary infections.[22](#jmv25499-bib-0022){ref-type="ref"} A study found that rhinovirus, the fastest‐growing virus, reduced the replication of the remaining viruses during a coinfection, while the replication of parainfluenza virus, the slowest‐growing virus, was suppressed in the presence of other viruses.[22](#jmv25499-bib-0022){ref-type="ref"} An early infection and a high number of viruses promote coinfection.[22](#jmv25499-bib-0022){ref-type="ref"} Therefore, further studies should focus on the coinfection of specific viruses and confirm the course of virus infection.

HPIV has four subtypes. HPIV3 manifests the major part of HPIV.[17](#jmv25499-bib-0017){ref-type="ref"} The tropism of HPIV1‐4 are different with each other. HPIV1 and HPIV2 are more likely to induce stridor and croup, while HPIV3 and HPIV4 have similar clinical presentations, and are more associated with hypoxia.[31](#jmv25499-bib-0031){ref-type="ref"}, [32](#jmv25499-bib-0032){ref-type="ref"} A study compared the clinical manifestations between HPIV3 and HPIV4 single infection and coinfection groups respectively, found no difference between the two groups. They did not compare the clinical manifestations of HPIV1 and HPIV2 due to the low number cases.[33](#jmv25499-bib-0033){ref-type="ref"} However, further classification of HPIV subtypes was not done in the present study. The severity of HPIV1‐4 coinfection remains unclear.

Neutrophilia were most commonly detected in patients with ADV and HRV.[17](#jmv25499-bib-0017){ref-type="ref"} Meanwhile, HRV, RSV, and ADV were the most frequent agents detected in coinfection. It might explain the result that neutrophil percentage in coinfection with viruses was higher than that in HPIV single infection. Another study found that the percentage of neutrophils was lower among children with single virus infection compared with mixed viruses and mixed virus/bacteria infection.[34](#jmv25499-bib-0034){ref-type="ref"} This might suggest it was a common phenomenon that coinfection increased the percentage of neutrophils. The mechanism needs further study.

Compared with HPIV single infection, coinfection with atypical bacteria was more related to running nose, moist rales, and longer hospital duration. Coinfection with atypical bacteria was also associated with longer hospital duration compared with coinfection with other viruses. It might indicate that HPIV coinfection with atypical bacteria led to more serious situations. Children with a viral coinfection with mycoplasma had significantly higher rates of running nose,[35](#jmv25499-bib-0035){ref-type="ref"} which might manifest the synergistic effect on running nose of the two kinds of pathogens. Coinfection with atypical bacteria was more related to moist rales, contrary to the typical clinical features of atypical bacteria single infection. Few studies have explored the coinfection with atypical bacteria. Hence, further studies are needed to confirm the findings.

The present study had several limitations. Children were evaluated at a single center and the number of patients enrolled was small, limiting the validity of virus‐specific clinical correlations in other settings. Also, the study was not double blind. In addition, the study lacked further division of HPIV 1 to 4 and analyses of the clinical characteristics of coinfection with bacteria. Last but not least, the study lacked long‐term follow‐up information.

In conclusion, this study demonstrated viral infections as the leading cause of lower respiratory tract illness, especially in children aged less than 3 years. The pathogens identified most frequently were RSV, HRV, HPIV, ADV, and HMPV. The coinfection rate was high. HPIV single infection was milder compared with coinfection with other viruses. Coinfection with atypical bacteria led to more serious situations compared with HPIV single infection and coinfection with other viruses.
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